top of page

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

  • 2 hours ago
  • 1 min read

Co-Founder & CEO Avencia Sánchez-Mejías describes the science of how they achieve this. At ASGCT, the company is presenting the second generation of FiCAT, and offers examples of introducing 3 or 4 genes.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page